CONMED CORPORATION Deferred Foreign Income Tax Expense (Benefit)
CONMED CORPORATION (CNMD) reported Deferred Foreign Income Tax Expense (Benefit) of -$1.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-17
- CONMED CORPORATION deferred foreign income tax expense (benefit) for fiscal 2025 was -$1.40M, a 219.32% decline from fiscal 2024.
- CONMED CORPORATION deferred foreign income tax expense (benefit) for fiscal 2024 was $1.17M.
- CONMED CORPORATION deferred foreign income tax expense (benefit) for fiscal 2023 was -$1.23M.
- CONMED CORPORATION deferred foreign income tax expense (benefit) for fiscal 2022 was -$310.00K.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$1.40M 10-K · filed 2026-02-17 |
| 2024-12-31 | $1.17M 10-K · filed 2026-02-17 |
| 2023-12-31 | -$1.23M 10-K · filed 2026-02-17 |
| 2022-12-31 | -$310.00K 10-K · filed 2025-02-18 |
| 2021-12-31 | -$1.91M 10-K · filed 2024-02-28 |
| 2020-12-31 | -$808.00K 10-K · filed 2023-02-21 |
| 2019-12-31 | -$1.40M 10-K · filed 2022-02-22 |
| 2018-12-31 | -$2.48M 10-K · filed 2021-02-22 |
| 2017-12-31 | $5.47M 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |